
Sinovac Biotech Ltd. – NASDAQ:SVA
Sinovac Biotech Ltd. stock price today
Sinovac Biotech Ltd. key metrics
Market Cap | 464.93M |
Enterprise value | N/A |
P/E | 6.66 |
EV/Sales | -12.01 |
EV/EBITDA | -41.65 |
Price/Sales | 1.25 |
Price/Book | 0.06 |
PEG ratio | N/A |
EPS | 38.78 |
Revenue | 24.46B |
EBITDA | 7.36B |
Income | 3.70B |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 21.61% |
Oper. margin | 42.23% |
Gross margin | 86.84% |
EBIT margin | 42.23% |
EBITDA margin | 30.1% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSinovac Biotech Ltd. stock price history
Sinovac Biotech Ltd. stock forecast
Sinovac Biotech Ltd. financial statements
Dec 2021 | 8.39B | 3.35B | 40.02% |
---|---|---|---|
Dec 2021 | 14.71B | -160.48M | -1.09% |
Jun 2022 | 1.21B | 484.51M | 39.97% |
Jun 2023 | 140.40M | 16.91M | 12.05% |
2025 | 742.63M | -11.95M | -1.61% |
---|
Analysts Price target
Financials & Ratios estimates
2023-01-30 | -0.045 | -0.03 |
---|
Payout ratio | 0% |
---|
2019 | |
---|---|
2020 | |
2021 | 291.95% |
2022 | 40.88% |
2023 | 50.91% |
Dec 2021 | 533671750505 | 503.12B | 94.28% |
---|---|---|---|
Jun 2022 | 15065784000 | 971.92M | 6.45% |
Dec 2022 | 14114568000 | 1.40B | 9.93% |
Jun 2023 | 13725010000 | 1.48B | 10.84% |
Jun 2021 | 9.08B | -3.27B | -29.99M |
---|---|---|---|
Dec 2021 | 6.26B | 251.30M | -1.86B |
Jun 2022 | -808.16M | -3.58B | 11.70M |
Jun 2023 | -39.99M | -2.73B | 217.16M |
Sinovac Biotech Ltd. alternative data
Aug 2023 | 1,959 |
---|---|
Sep 2023 | 1,959 |
Oct 2023 | 1,959 |
Nov 2023 | 1,959 |
Dec 2023 | 1,959 |
Jan 2024 | 1,959 |
Feb 2024 | 1,959 |
Mar 2024 | 1,959 |
Apr 2024 | 1,959 |
May 2024 | 1,959 |
Jun 2024 | 1,959 |
Jul 2024 | 1,959 |
Sinovac Biotech Ltd. other data
Period | Buy | Sel |
---|---|---|
Sep 2003 | 0 | 12572700 |
Nov 2003 | 0 | 6027870 |
Quarter | Transcript |
---|---|
Q3 2016 28 Nov 2016 | Q3 2016 Earnings Call Transcript |
Q2 2016 23 Aug 2016 | Q2 2016 Earnings Call Transcript |
Q1 2016 27 May 2016 | Q1 2016 Earnings Call Transcript |
Q4 2015 5 Apr 2016 | Q4 2015 Earnings Call Transcript |
Insider | Compensation |
---|---|
Dr. Weidong Yin Chairman, Chief Executive Officer, Pres, MD, GM & Sec. | |
Ms. Xiaomei Yin Vice President of Sales & Marketing | |
Ms. Nan Wang Chief Financial Officer & Vice President of Bus. Devel. |
-
What's the price of Sinovac Biotech Ltd. stock today?
One share of Sinovac Biotech Ltd. stock can currently be purchased for approximately $6.47.
-
When is Sinovac Biotech Ltd.'s next earnings date?
Unfortunately, Sinovac Biotech Ltd.'s (SVA) next earnings date is currently unknown.
-
Does Sinovac Biotech Ltd. pay dividends?
No, Sinovac Biotech Ltd. does not pay dividends.
-
How much money does Sinovac Biotech Ltd. make?
Sinovac Biotech Ltd. has a market capitalization of 464.93M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 69.97% to 448.27M US dollars. Sinovac Biotech Ltd. made a loss 99.92M US dollars in net income (profit) last year or -$0.03 on an earnings per share basis.
-
What is Sinovac Biotech Ltd.'s stock symbol?
Sinovac Biotech Ltd. is traded on the NASDAQ under the ticker symbol "SVA".
-
What is Sinovac Biotech Ltd.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Sinovac Biotech Ltd.?
Shares of Sinovac Biotech Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Sinovac Biotech Ltd.'s key executives?
Sinovac Biotech Ltd.'s management team includes the following people:
- Dr. Weidong Yin Chairman, Chief Executive Officer, Pres, MD, GM & Sec.
- Ms. Xiaomei Yin Vice President of Sales & Marketing
- Ms. Nan Wang Chief Financial Officer & Vice President of Bus. Devel.
-
How many employees does Sinovac Biotech Ltd. have?
As Jul 2024, Sinovac Biotech Ltd. employs 1,959 workers.
-
When Sinovac Biotech Ltd. went public?
Sinovac Biotech Ltd. is publicly traded company for more then 21 years since IPO on 26 Sep 2003.
-
What is Sinovac Biotech Ltd.'s official website?
The official website for Sinovac Biotech Ltd. is sinovacbio.com.
-
How can i contact Sinovac Biotech Ltd.?
Sinovac Biotech Ltd. can be reached via phone at +86 10 8289 0088.
Sinovac Biotech Ltd. company profile:

Sinovac Biotech Ltd.
sinovacbio.comNASDAQ
1,959
Biotechnology
Healthcare
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.
Beijing,
CIK: 0001084201
ISIN: AGP8696W1045
: